Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme.

Results confirm findings from clinical trials, demonstrating that mepolizumab is associated with important improvements in several clinically meaningful outcomes and has a favourable safety profile in a population with severe eosinophilic asthma, outside of the controlled environment of a clinical trial.